scholarly journals Real-World Data on Frontline (FL) Treatments in Multiple Myeloma (MM) Patients across EU5 Countries

Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 5858-5858
Author(s):  
Joana Anjo ◽  
Alex Rider ◽  
Abigail Bailey ◽  
Maren Gaudig
Keyword(s):  
Data Collection ◽  
Real World ◽  
Stem Cell Transplant ◽  
Standard Of Care ◽  
Cell Transplant ◽  
Summary Statistics ◽  
Real World Data ◽  
World Data ◽  
Induction Regimen ◽  
Number Of Cycles

Abstract Objective This analysis was conducted to understand the clinical practice on FL treatment in patients with MM across EU5 countries. Methods Real world data were collected through Adelphi's Disease-Specific ProgrammeTM - a point in time survey administered to physicians (n=241) in EU5 countries between Nov 2017 - Feb 2018. Stem Cell Transplant eligibility and treatments, including number of cycles and dosage, were collected from patient record forms (n=1952). Summary statistics were reported and analysed descriptively. Results Data on FL treatment was collected for 1952 patients; 988 (51%) were still on FL treatment at the time of data collection. Bortezomib-based regimens were used in more than 70% of patients - in both transplanted/transplant eligible (TE, n=572) and non-transplanted/transplant ineligible patients (TIE, n= 1380). In TIE patients, bortezomib, melphalan and dexamethasone (VMP) was the most commonly used regimen, covering almost one third of the patients (31%), followed by bortezomib, either in combination with cyclophosphamide and dexamethasone (VCD, 10%) or thalidomide and dexamethasone (VTD, 10%). The other two FL regimens currently approved in Europe - thalidomide, melphalan and dexamethasone (MPT) and lenalidomide and dexamethasone (Rd) have patient shares of 9% each. When analyzing the TIE patients undergoing FL treatment at time of data collection (n=606), VMP remained the most used regimen (29%) and Rd the second (15%), with VTD and MPT being used in 8% of patients. In TE patients, VTD was the most commonly used induction regimen, being used in 50% of patients, followed by VCD (21%). The numbers remained the same when analyzing the TE patients in FL treatment at time of data collection (n=382), with 54% and 22% using VTD and VCD, respectively. Conclusions Collectively these results indicate that bortezomib-based regimens remain the standard of care in FL treatment of MM in EU5, in both transplant and non-transplant settings. Disclosures Anjo: Janssen: Employment. Rider:Adelphi Real World: Employment. Bailey:Adelphi Real World: Employment. Gaudig:Janssen: Employment.

scholarly journals Utilizing HealthTree ® Cure Hub's Real-World Data to Assess Treatment Management of Patients with Multiple Myeloma during the COVID-19 Pandemic

Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 5026-5026
Author(s):  
Nathan W. Sweeney ◽  
Jennifer M. Ahlstrom
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Real World ◽  
Online Survey ◽  
Stem Cell Transplant ◽  
Oral Treatment ◽  
Cell Transplant ◽  
Real World Data ◽  
World Data ◽  
Treatment Management

Abstract Background: Patients with multiple myeloma (MM) are uniquely susceptible to viral and bacterial illnesses, including COVID-19, due to their immunocompromised state, age, treatments, and comorbidities. With the advent of COVID-19, changes to treatment were recommended whenever possible, in order to reduce visits to the clinic. The total effect of these changes on cancer patients with multiple myeloma remains unclear. The aim of this project was to assess treatment management by changes to treatment of patients with MM during the COVID-19 pandemic. Methods: We utilized HealthTree ® Cure Hub for Multiple Myeloma (healthree.org) and invited patients with active MM cancer or precursor conditions to participate in an online survey. We analyzed patient responses to questions regarding their myeloma treatments during the COVID-19 pandemic. Results: 978 MM patients participated in the survey between February to June 2021. Since March 2020, 151 patients (15%) either delayed, postponed, or stopped a myeloma treatment because of COVID-19. The four most common treatments were daratumumab (20%), lenalidomide (15%), stem cell transplant (13%) and zoledronic acid (11%). There were 110 patients that canceled a planned myeloma treatment. Of these patients, 55 (50%) canceled a planned chemotherapy, 15 (14%) canceled a stem cell transplant, 1 (1%) canceled radiation and 39 (35%) indicated other. Eight patients replaced an intravenous or subcutaneous treatment with an oral treatment because of COVID-19. There were 9 patients that started a new myeloma treatment because of COVID-19, the most common being daratumumab (44%), ixazomib (22%), lenalidomide (22%) and carfilzomib (11%). Finally, 15 patients had their lenalidomide (50%), steroid (42%) and carfilzomib (8%) dose changed. Conclusions: Our results show that decision-making regarding treatment changes were made on an individual basis and that patients who required a change in treatment were the minority. Aggregating real-world data can provide evidence that despite the changes, patients with MM still received and efficacious treatment and avoided putting these patients at risk or mortality. Disclosures Ahlstrom: Bristol Myers Squibb: Other: Patient Advisory; Janssen: Other: Patient Advisory; Pfizer: Other: Patient Advisory; Takeda: Other: Patient Advisory.

MM-257: It’s the Response That Matters: Real-World Data of Multiple Myeloma Patients Treated without Upfront Stem Cell Transplant

2021 ◽  
Vol 21 ◽  
pp. S433
Author(s):  
Rohit Reddy Lavu ◽  
Lalit Kumar ◽  
Raja Mounika Velagapudi ◽  
Sreenivas Konda ◽  
Shalabh Arora
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Real World ◽  
Stem Cell Transplant ◽  
Cell Transplant ◽  
Real World Data ◽  
World Data

scholarly journals Comparison of Cycling Behavior between Keyboard-Controlled and Instrumented Bicycle Experiments in Virtual Reality

2020 ◽  
Vol 2674 (7) ◽  
pp. 244-257
Author(s):  
Martyna Bogacz ◽  
Stephane Hess ◽  
Chiara Calastri ◽  
Charisma F. Choudhury ◽  
Alexander Erath ◽  
...  
Keyword(s):  
Virtual Reality ◽  
Experimental Design ◽  
Data Collection ◽  
Real World ◽  
Head Movements ◽  
Behavioral Data ◽  
Experimental Setup ◽  
Real World Data ◽  
World Data ◽  
Cycling Behavior

The use of virtual reality (VR) in transport research offers the opportunity to collect behavioral data in a controlled dynamic setting. VR settings are useful in the context of hypothetical situations in which real-world data does not exist or in situations which involve risk and safety issues making real-world data collection infeasible. Nevertheless, VR studies can contribute to transport-related research only if the behavior elicited in a virtual environment closely resembles real-world behavior. Importantly, as VR is a relatively new research tool, the best-practice with regards to the experimental design is still to be established. In this paper, we contribute to a better understanding of the implications of the choice of the experimental setup by comparing cycling behavior in VR between two groups of participants in similar immersive scenarios, the first group controlling the maneuvers using a keyboard and the other group riding an instrumented bicycle. We critically compare the speed, acceleration, braking and head movements of the participants in the two experiments. We also collect electroencephalography (EEG) data to compare the alpha wave amplitudes and assess the engagement levels of participants in the two settings. The results demonstrate the ability of VR to elicit behavioral patterns in line with those observed in the real-world and indicate the importance of the experimental design in a VR environment beyond the choice of audio-visual stimuli. The findings will be useful for researchers in designing the experimental setup of VR for behavioral data collection.

Activities for Students: As the Ball Rolls: A Quadratic Investigation Using Multiple Representations

2009 ◽  
Vol 103 (1) ◽  
pp. 62-68
Author(s):  
Kathleen Cage Mittag ◽  
Sharon Taylor
Keyword(s):  
Data Collection ◽  
Real Time ◽  
Physical Model ◽  
Real World ◽  
Graphing Calculator ◽  
Data Sets ◽  
Real World Data ◽  
World Data ◽  
Hands On ◽  
Modeling Data

Using activities to create and collect data is not a new idea. Teachers have been incorporating real-world data into their classes since at least the advent of the graphing calculator. Plenty of data collection activities and data sets exist, and the graphing calculator has made modeling data much easier. However, the authors were in search of a better physical model for a quadratic. We wanted students to see an actual parabola take shape in real time and then explore its characteristics, but we could not find such a hands-on model.

scholarly journals PNS1 Real-World DATA Collection in China: Challenges and Recommendations to Ensure DATA Quality

2020 ◽  
Vol 22 ◽  
pp. S80
Author(s):  
M. Soni ◽  
L. Marshall ◽  
R. Zaha ◽  
J. Lee ◽  
Y. Huang
Keyword(s):  
Data Collection ◽  
Data Quality ◽  
Real World ◽  
Real World Data ◽  
World Data
Sign in / Sign up

Export Citation Format

Share Document